Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ASA plus Clopidogrel Clear all
Completed Not applicable Interventional

The Effects of MAP and EtCO2 on Venous Sinus Pressures

NCT03867461
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Venous Sinus Stenting, Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range), Adjustment to Mean Arterial Pressure (100-110 mmHg range), Adjustment to Mean Arterial Pressure (60-80 mmHg range), Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 24, 2026, 4:28 AM EDT
Terminated Phase 3 Interventional Results available

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

NCT02556203
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic Acid (ASA), Clopidogrel, Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
31
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 24, 2026, 4:28 AM EDT
Not listed Phase 4 Interventional Results available

CYPRESS - CYPHER for Evaluating Sustained Safety

NCT00954707
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel & Aspirin, Prasugrel & Aspirin, Placebo & Aspirin
Drug
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
2,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

NCT00335452
View directory record Official record
Conditions
Acute Coronary Disease, Angina Unstable
Interventions
Clopidogrel, acetylsalicyclic acid (ASA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
25,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Results available

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

NCT01241903
View directory record Official record
Conditions
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions
rosuvastatin, placebo
Drug
Lead sponsor
Susan Smyth
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus

NCT04484259
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 24, 2026, 4:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation

NCT03746782
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Flow Cytrometry; Thrombin Generation Assay
Diagnostic Test
Lead sponsor
CirQuest Labs, LLC
Other
Eligibility
18 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

NCT01557335
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Drug
Lead sponsor
POZEN
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

Vorapaxar on Thrombin Generation and Coagulability

NCT03207451
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Vascular Disease, Myocardial Infarction
Interventions
Vorapaxar, Vorapaxar and Aspirin, Vorapaxar and Clopidogrel, Vorapaxar, Aspirin, and Clopidogrel
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants

NCT01511939
View directory record Official record
Conditions
Osteoarthritis of the Knee, Coagulopathy
Interventions
Pennsaid
Drug
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 3 Interventional

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

NCT00007683
View directory record Official record
Conditions
Heart Failure
Interventions
Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Not applicable Interventional

Low Risk Acute Coronary Syndrome

NCT01703156
View directory record Official record
Conditions
Low Risk Acute Coronary Syndrome
Interventions
Stress Test, No Stress Test
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 24, 2026, 4:28 AM EDT
Not listed Phase 4 Interventional

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

NCT03150667
View directory record Official record
Conditions
Chronic Kidney Diseases, Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

Prasugrel/Clopidogrel Maintenance Dose Washout Study

NCT01014624
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
La Jolla, California • Jacksonville, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 4 Interventional

Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel

NCT02567461
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Edoxaban 60 mg, Edoxaban 30 mg, Clopidogrel 75 mg, Aspirin 81 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 24, 2026, 4:28 AM EDT
Terminated Phase 4 Interventional

Ticagrelor and Peripheral Arterial Disease

NCT02407314
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Percutaneous Peripheral Intervention, Optical Coherence Tomography, Ankle Brachial Index, Six minute walk distance, Aspirin, Aspirin + Ticagrelor
Procedure · Device · Other + 1 more
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 24, 2026, 4:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)

NCT02094755
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Blood draw only
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 24, 2026, 4:28 AM EDT
Not listed No phase listed Observational

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

NCT01086163
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Omacor, omega-3 fatty acids in CAD patients
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
50 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

NCT00357968
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Sep 24, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 24, 2026, 4:28 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin plus clopidogrel, prasugrel or ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 24, 2026, 4:28 AM EDT
Active, not recruiting Not applicable Interventional

SIMPLAAFY Clinical Trial

NCT06521463
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
WATCHMAN FLX Pro LAAC Device
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 24, 2026, 4:28 AM EDT